Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $359.30 million. The enterprise value is $161.58 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 108.22 million shares outstanding. The number of shares has increased by 14.70% in one year.
| Current Share Class | 108.22M |
| Shares Outstanding | 108.22M |
| Shares Change (YoY) | +14.70% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 66.84% |
| Float | 78.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.30, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.30 |
| Quick Ratio | 7.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -130.71 |
Financial Efficiency
Return on equity (ROE) is -74.88% and return on invested capital (ROIC) is -44.51%.
| Return on Equity (ROE) | -74.88% |
| Return on Assets (ROA) | -40.56% |
| Return on Invested Capital (ROIC) | -44.51% |
| Return on Capital Employed (ROCE) | -73.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$805,726 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.55% in the last 52 weeks. The beta is 0.65, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -75.55% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 4.56 |
| Relative Strength Index (RSI) | 51.70 |
| Average Volume (20 Days) | 2,008,638 |
Short Selling Information
The latest short interest is 11.56 million, so 10.68% of the outstanding shares have been sold short.
| Short Interest | 11.56M |
| Short Previous Month | 11.03M |
| Short % of Shares Out | 10.68% |
| Short % of Float | 14.63% |
| Short Ratio (days to cover) | 4.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -247.18M |
| Pretax Income | -240.91M |
| Net Income | -240.91M |
| EBITDA | -236.01M |
| EBIT | -247.18M |
| Earnings Per Share (EPS) | -$2.24 |
Full Income StatementBalance Sheet
The company has $222.76 million in cash and $25.05 million in debt, giving a net cash position of $197.71 million or $1.83 per share.
| Cash & Cash Equivalents | 222.76M |
| Total Debt | 25.05M |
| Net Cash | 197.71M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 313.67M |
| Book Value Per Share | 2.90 |
| Working Capital | 196.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$202.12 million and capital expenditures -$669,000, giving a free cash flow of -$202.79 million.
| Operating Cash Flow | -202.12M |
| Capital Expenditures | -669,000 |
| Free Cash Flow | -202.79M |
| FCF Per Share | -$1.87 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |